Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine

Inclusion Criteria

• Between 18 and 50 years old
• Free of chronic medical conditions requiring ongoing therapy and in general good health as determined by a physician investigator
• Have a current (within 30 days of scheduled blood donation for this study) complete blood (cell) count (CBC) to include a Hct and Hgb that show no evidence of anemia, and total white blood cell with differential platelet counts that are within normal range, as well as hepatic enzyme (AST, ALT, LDH) values that are within normal laboratory ranges
• Negative human immunodeficiency virus (HIV) antibody test within 3 months preceding vaccination
• No evidence of pre-existing liver disease or current infection with Hepatitis A, B, or C virus as determined by serology
• No evidence for pre-existing eye disease, as determined by fundoscopic/slit lamp examination by the study ophthalmologist other than refractory changes
• No evidence by history or serologic testing for previous infection with RVF virus or RVF vaccine
• Subjects must agree to refrain from intimate contact (sexual activity), or use barrier contraception (e.g., condoms), for the 2-week period following vaccination
• Females of child-bearing potential must have a negative serum pregnancy test on screening and the morning of vaccination prior to receipt of the vaccine and must agree to use a highly effective method of birth control during the first 3 months following receipt of the MP-12 vaccine. A highly effective method of birth control is defined as one with a failure rate of less than 1% per year. Acceptable birth control methods that meet this criterion include hormonal implants and injectables (Norplant, Dep-Provera, Lunelle, and Etonogestrel); combined oral contraceptives; the intrauterine devices (IUDs) Copper T (380-A) or Mirena (Levonorgestrel Intrauterine System); female sterilization (tubal ligation); sexual abstinence; or a vasectomized partner.
• Subjects must be medically cleared for participation by an investigator
• Subjects must expect to remain in the area for the duration of the study
• Volunteer must sign an approved informed consent
• Volunteer must be willing to return for all follow-up visits including a post-vaccination ophthalmologic visit
• Volunteer must be willing to refrain from excessive (more than individual's normal routine) exercise for a period of at least 2 weeks prior to and following vaccination
• Volunteer must be willing to abstain from drinking alcoholic beverages for a period of at least 2 weeks prior to and following vaccination. Volunteer must not be a "weekend" drinker or normally drink more than 2 drinks a day if male or 1 drink a day if female.
• Volunteer must agree to report any adverse event (AE) that may or may not be associated with administration of the test article during their participation in the study.

Exclusion Criteria

• History or evidence of liver disease/abnormality
• History of pre-existing thymic disease or thymic dysfunction (any cellular immune or antibody disorders)
• Be taking any medication, prescription or non-prescription (excluding dietary supplements), on a regular basis with the exception of contraceptive pills. This includes the regular use of statins, non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressive agents, antivirals, topical steroidal creams, and nasal sprays. Conditions requiring intermittent medications and other decisions regarding eligibility due to medication use will be deferred to physician investigators.
• Elevation above the upper limit of laboratory normal values in liver enzymes, or history of unexplained elevation in liver enzymes
• History or evidence of eye disease (excluding changes in refraction and strabismus)
• Abnormal clinical lab results indicating evidence of anemia, immunosuppression, or immune deficiency disease
• Have donated 1 unit (500 cc) or more of blood for any reason during the 2 months (56 days) preceding administration of the vaccine (as assessed by query)
• Pla